We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Zc6.0
Zinc Carnosine Research
Likely helps
59 peer-reviewed studies
What the evidence says
Likely helps
Zinc Carnosine appears to help in 11 of 13 studies with measurable effects — the evidence leans clearly favourable.
Most evidence is from high-quality meta-analyses and randomised trials published 1998–2026 with a typical study size of 83 participants.
Based on 59 studies · 10 meta-analyses · 45 RCTs · 275,527 total participants
Confidence
High confidence
What the studies found
11helped1unclear1didn't help· 46 more without graded effect data
By outcome
Wound & ulcer healing
Likely helps45 studies
Gut barrier & GIImproved gut lining integrity and reduced stomach discomfort within 4-8 weeks · 4-8 weeks
Likely helps42 studies
Therapeutic & clinical
Mostly mechanism / observational11 studies
Safety profile
Probably helps6 studies
InflammationHealed gut lining and reduced inflammation · 4-8 weeks
Too few graded studies1 study
By the numbers
Pulled from 27 studies with measurable effects
Likely real effects
92%
across studies
People studied
276k
typical study: 83 people
Strongest designs
55
10 pooled, 45 randomised
Showed benefit
85%
11/13 studies
How long studies ran
1–4 weeks
2
1–3 months
4
3+ months
2
Populations Studied
Patients with H. pylori infection2
Patients with pressure ulcers2
Patients with gastric ulcers and H. pylori infection1
Patients with age-related diseases1
Steady research
17 studies in the last 5 years · Latest meta-analysis: 2026
199820122026
1Meta-Analysis2023
Sureshkumar K, Durairaj M, Srinivasan K, Goh KW, Undela K, Mahalingam VT · Front Biosci (Landmark Ed) (2023)
7H. pylori eradication rateMeta-AnalysisCited 3×n=396 · medium study2022
However, the evidence is still scarce, and larger trials are needed to confirm or refute our findings.
Mahmoud A et al. · Nutrients (2022)
Huge harm
← WorseNo effectBetter →
Likely real
We used the odds ratio (OR) for dichotomous outcomes presented with the corresponding 95% confidence interval (CI).
Pooled OR found a statistical difference favoring the PZN arm in the intention to treat and per protocol H. pylori eradication rates (OR: 2.01 with 95% CI [1.27, 3.21], p = 0.003) and (OR: 2.65 with 95% CI [1.55, 4.54], p = 0.0004), respectively.
We found no statistical difference between the two groups regarding the total adverse events (OR: 1.06 with 95% CI [0.55, 2.06], p = 0.85).
Clinical studies were conducted to manage chemotherapy induced toxicities and there are no clinical studies available for its anti-cancer use, and the current evidence does not support its use in the treatment of cardiovascular disease.
Sureshkumar K et al. · Frontiers in bioscience (Landmark edition) (2023)
Clinical studies were conducted to manage chemotherapy induced toxicities and there are no clinical studies available for its anti-cancer use, and the current evidence does not support its use in the treatment of cardiovascular disease.
The dose of 300 mg may be useful among patients with baseline serum zinc concentration of less than 70 µg/dL, and 150 mg for 70 µg/dL or more.
Furihata K et al. · Nutrients (2020)
Noticeable benefit
← WorseNo effectBetter →
Likely real
The dose-combined overall polaprezinc increased the change from baseline by a mean of 9.08 µg/dL (95% confidence interval: 5.46, 12.70; heterogeneity: I2 = 0.61%) compared to the placebo.
A significant dose-response relationship was confirmed (p < 0.001).
Baseline serum zinc concentration was considered an effect modifier in polaprezinc 300 mg.
14Gastric ulcer healing rateRCTCited 2×n=224 · medium study2022
These findings suggest that the efficacy and safety of polaprezinc were similar to those of rebamipide in the treatment of GU.
Shen W et al. · Medical engineering & physics (2022)
Huge benefit
← WorseNo effectBetter →
Could be chance
For the primary efficacy endpoint, the effective rates confirmed by gastroscopy, after treatment for the test and control groups were 81.48% and 74.31% (P = 0.1557), respectively.
After 4 and 8 weeks of treatments, both treatment groups had comparable improvements rates in gastrointestinal symptoms (test vs. control: 44.44% vs. 39.45% [P = 0.4559] and 81.48% vs. 77.06% [P = 0.4223]).
These findings suggest that the efficacy and safety of polaprezinc were similar to those of rebamipide in the treatment of GU.
15H. pylori eradication rateRCTCited 22×n=303 · medium study2017
It appears that standard dose polaprezinc combined with triple therapy can significantly improve the H. pylori eradication rate, without an increase in toxicity.
Tan B et al. · PloS one (2017)
Huge benefit
← WorseNo effectBetter →
Likely real
Intention-to-treat (ITT) analysis showed that the rate of H. pylori eradication was significantly higher for Arms A (77.0%) and B (75.9%) compared to Arm C (58.6%) (P < 0.01), whereas there was no difference between Arms A and B (P = 0.90).
Per-protocol (PP) analysis showed that the rate of H. pylori eradication was significantly higher for Arms A (81.1%) and B (83.3%) compared to Arm C (61.4%) (P < 0.01), whereas there was no significant difference between Arms A and B (P = 0.62).
The adverse event rate for Arm B (5.1%) was higher than for Arms A (2.8%) (P = 0.04) and C (1.9%) (P = 0.02).